Johnson DC et al. - The evolutionary history of multiple myeloma (MM) predicts patient outcome and personalising therapy.

Methods
Whole exome sequencing tumor data for 333 patients, all of who had received immunomodulatory therapy (IMiD), were analyzed. 

Results
17%-20% of MM is under neutral evolutionary dynamics.
MM is associated with poorer patient survival in non-intensively treated patients.